Interactions of Colorectal Cancer, Dietary Fats, and Polymorphisms of Arachidonate Lipoxygenase and Cyclooxygenase Genes: A Literature Review

Maryam Gholamalizadeh¹, Nazanin Majidi², Shirin Tajaddod², Sepideh Abdollahi³, Seyed Mohammad Poohosseini⁴, Mina Ahmadzadeh⁵, Mohammad Naimi Joubani⁶, Samaneh Mirzaei Dahka⁷, Hanieh Shafaei⁷, Moghe Hajiesmaei⁸, Atiyeh Alizadeh⁹, Saeid Doaei¹⁰* and Anahita Houshiar-Rad¹¹*

¹ Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ² Department of Nutrition, Science and Research Branch, Islamic Azad University, Tehran, Iran, ³ Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, ⁴ Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ⁵ Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ⁶ Research Center of Health and Environment, School of Health, Guilan University of Medical Sciences, Rasht, Iran, ⁷ Nursing and Midwifery School, Guilan University of Medical Sciences, Rasht, Iran, ⁸ Department of Biology and Biotechnology “Charles Darwin”, Sapienza University of Rome, Rome, Italy, ⁹ Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran, ¹⁰ Reproductive Health Research Center, Department of Obstetrics and Gynecology, School of Medicine, Al-Zahra Hospital, Guilan University of Medical Sciences, Rasht, Iran, ¹¹ Dept. of Nutrition Research, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Objective: Genetics and dietary factors play important roles in the development of colorectal cancer (CRC). However, the underlying mechanisms of the interactions between CRC, gene polymorphisms, and dietary fat are unclear. This review study investigated the effects of polymorphisms of arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) genes in the association between CRC and dietary fat.

Methods: All the related papers published from 2000 to 2022 were collected from different databases such as PubMed, Science Direct, Scopus, and Cochran using related keywords such as colorectal cancer, ALOX, COX, polymorphism, and dietary fat. Non-English and unrelated documents were excluded.

Results: Some single-nucleotide polymorphisms (SNPs) in the ALOX and COX genes, such as rs2228065, rs6413416, and rs4986832 in the ALOX gene, and rs699465 in the COX gene may play significant roles in the association between the risk of CRC and dietary fats. SNPs of ALOX and COX genes may influence the effects of dietary fatty acids on the risk of CRC.
**INTRODUCTION**

Colorectal cancer (CRC) is the second leading cause of cancer death in women and the third in men worldwide (1) and cause about 0.9 million deaths worldwide in 2020 (2). It has been reported that CRC originates from a combination of genetic, environmental, and behavioral risk factors. Some behavioral factors are associated with dietary intake, including higher intake of calories, red meat, and fats (3, 4).

Recently, various types of fatty acids have been reported as effective dietary factors in CRC development. Some fatty acids, such as saturated fatty acids, may have an adverse effect, whereas other fatty acids, such as omega-3 fatty acids, may have a beneficial effect on CRC prevention (5–7). One main mechanism through which dietary polyunsaturated fatty acids (PUFAs) may affect colonic carcinogenesis is the formation of specific eicosanoids (oxygenated metabolites of PUFAs) such as prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs) (7). Two enzymatic pathways related to the synthesis of these eicosanoids are the arachidonic lipoxygenase (ALOX) pathways and prostaglandin-endoperoxide synthase (PTGS), which are also known as cyclooxygenase (COX) pathways (8). The function of ALOX enzymes, such as ALOX5, ALOX12, and ALOX15, eventually leads to LT and LX formation, and the COX enzymes, like COX1 and COX2, result in the production of PGs and TXs (9, 10). Evidence has shown that changes in the sequence of COX and ALOX genes as single-nucleotide polymorphisms (SNPs) can influence the risk of CRC (8).

In terms of ALOX, previous research has established that ALOX15 expression and concentration of eicosanoic metabolites are reduced in polyps and colorectal tumors in humans (11). In contrast, increased ALOX5 expression has been reported in colorectal cancer cells (12). Moreover, it has been reported that some mutations in ALOX12 are associated with tumorogenesis in epithelial cancers (13). Recent studies have identified that the expression level of the COX2 gene and the levels of its metabolites, such as PGE2, PGD2, and PGF2α, are significantly increased in the colon of obese mice. Also, it has been shown that the administration of COX2 inhibitors can suppress inflammation, tumor growth, and tumor metastasis (14–16).

Notably, the effect of dietary fats on the risk of CRC may be influenced by gene polymorphisms (17–19). However, the interactions between CRC, dietary fat, and gene polymorphisms are still unknown. So, this review study investigated the effects of SNPs of the ALOX and COX genes on the association between dietary fats and CRC risk.

**MATERIALS AND METHODS**

**Search Strategy**

The literature search was performed using the PubMed, Science Direct, Scopus, and Cochran databases, and all related papers published from 2000 to 2022 were collected using the following keywords: “dietary fat or fatty acid or fat or lipid” and “ALOX or COX or prostaglandin-endoperoxide synthase or PTGS or cyclooxygenase or COX or arachidonic lipooxygenase or lipoxygenase” and “colorectal cancer or colon cancer or rectal cancer” and “polymorphism or genetic variation or genotype or SNP.” All the collected papers and their references were reviewed.

**Inclusion and Exclusion Criteria**

All studies that examined the interaction of colorectal cancer with ALOX and COX genes, studies concerning the relationship between the ALOX and COX gene polymorphisms, and studies on the interactions between colorectal cancer, ALOX and COX genes, and dietary fat were included in this study. Unrelated and non-English papers, the review studies, studies on the relationship between ALOX and COX with other cancers, and animal studies were excluded.

**Assessment of Methodological Rigor**

In this review study, the quality of the collected studies was assessed by four researchers (MG, HS, SA, and SD). In the case of having opposing ideas, other researchers (MH and HS) would be involved in reaching an agreement. After collecting the papers, all unrelated studies were excluded from the review process according to their titles and abstracts. Then, the full texts of the relevant articles were studied precisely. The standard quality assessment method of the 'EPOC Risk of Bias Tool' was applied to assess the quality of the methodologies (20). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist (21) was used to extract the required data from the included studies. Finally, the data about the participants, intended comparisons, obtained results, and study planning (PICO) were collected.

**RESULTS**

**Description of the Identified Studies**

The process of including the appropriate studies is presented in Figure 1. A total of 413 articles were collected in the primary search, of which 354 articles were excluded after the screening of their titles and abstracts. Also, 28 articles were excluded after
reading the full texts. Finally, 31 articles qualified to be included in the review process. All articles were published from 2000 to 2022 and were related to the interactions between CRC, ALOX, and COX genes and fat intake. The main characteristics of the studies are presented in Tables 1, 2.

**Arachidonate Lipoxygenase (ALOX) Gene Polymorphisms and Risk of CRC**

The primary function of ALOX is to convert arachidonic acid (AA) into hydroperoxyeicosatetraenoic acid (HPEtE) and eventually leukotrienes, a class of paracrine hormones involved...
in the inflammatory response. For example, ALOX12 converts AA into 12-hydroperoxycicosaatetraenoic acid (12-HPETE), which is involved in the expression of pro-inflammatory cytokine genes such as tumor necrosis factor-α (TNF-α) (36). The role of the ALOX gene in inflammatory diseases and colorectal neoplasia has been frequently reported. For example, the arachidonate-5 lipoxygenase (ALOX5) and 12-lipoxygenase (ALOX12) played pro-carcinogenic roles in colorectal cancer (22). Additionally, overexpression of ALOX5 with its related downstream metabolites has been reported in other cancers such as breast, esophageal, pancreatic, and prostate cancers by stimulation of cell proliferation, tumor angiogenesis, and survival (37). Moreover, it has been reported that ALOX15 is associated with an increased risk of colorectal cancer, particularly in people with higher inflammatory factors (38). In another study, Ruan et al. examined the diagnostic and prognostic values of the ALOX gene family mRNA expression in 438 colon adenocarcinoma tumor samples and 41 adjacent tissue samples of Chinese patients by bioinformatics analysis. They showed that the expression level of ALOX3, ALOX5, ALOX12, and ALOX12B was upregulated in colorectal tumor samples. Finally, they reported that ALOX3 and ALOX12 might serve as potential independent prognostic indicators of colon adenocarcinoma (25). Thus, ALOX pathways in the AA metabolism process can be considered crucial pathways in the development of CRC (Figure 2).

Notably, specific polymorphisms of the ALOX gene can affect the susceptibility to CRC. For instance, Goodman et al. assessed the effects of ALOX5 and ALOX12 gene polymorphisms on CRC in African-Americans and Caucasian patients. They found that the rs6413416 and rs4986832 polymorphisms of ALOX5 were associated with a decreased risk of CRC in Caucasians. They hypothesized that these polymorphisms could improve binding to the promoter region, leading to downregulation of ALOX5. In this way, they can lower the cancer risk by reducing enzymatic activity (8). However, the rs4986832 polymorphisms of ALOX5 had no association with the risk of colorectal polyps in Minnesota (24). Kleinsein et al. conducted a study on 2447 cases and 3133 controls regarding the effect of ALOX gene polymorphisms on the risk of CRC. The results showed that the rs2073438 polymorphism of ALOX 12 was related to a lower risk of rectal cancer (OR = 0.66, 95% CI: 0.42–0.104), while the rs4796535 and rs2619112 polymorphisms of ALOX15 were associated with an increased risk of rectal cancer (OR = 1.43,
95% CI: 1.03–1.97 and OR = 1.13, 95% CI: 0.85–1.55, respectively) (22). Moreover, a positive association was found between the ALOX12 rs1126667 polymorphism and a moderately increased risk of CRC (OR = 1.38, 95% CI: 1.09–1.74) (23). However, the association between rs1126667 polymorphism of ALOX12 and the risk of CRC has been reported in African-Americans and Caucasian patients (8). This discrepancy can be due to differences in ethnic or statistical power. A summary of studies on the association between ALOX polymorphisms and CRC is provided in Table 1.

**Cyclooxygenase (COX) Gene Polymorphism and Risk of CRC**

Prostaglandin H synthase, also known as cyclooxygenase and prostaglandin-endoperoxide synthase (PTGS), catalyzes the first step in the biosynthesis of all prostaglandins and prostacyclins by converting arachidonic acid to prostaglandin H (39). Two forms of human PTGS, PTGS1 and PTGS2 (COX1 and COX2), can be inhibited by non-steroidal anti-inflammatory drugs (NSAIDs). Also, the end products of COX are related to various biological pathways in stimulating tumor growth (26) (Figure 3). Prostaglandins are upregulated in colorectal cancer, and it was reported that genetic polymorphisms in both COX1 and COX2 are associated with CRC (27, 37). COX2 is involved in cell cycle control, and increased expression of COX-2 in CRC patients compared to normal controls indicates its possible role in the progression of CRC (40). COX2 influences cancer progression by increasing prostaglandin production, preventing tumor cell apoptosis, cell proliferation, and tumor angiogenesis (41). It was reported that aspirin plays a key role in preventing colon cancer by inhibiting COX (37). Ayiomamitis et al. examined the expression of COX1, COX2, prostaglandin-endoperoxide synthase 3 (PTGES3), and telomerase reverse transcriptase (TERT). They used bioinformatics analysis on the Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD) and rectal adenocarcinoma (READ) datasets. The results showed an inverse relationship between COX2 expression and telomerase activity in CRC. In the end, they identified differentially methylated patterns within the promoter regions of COX2 and TERT (42). Joanna et al. observed COX2 overexpression in the early stages of colorectal cancer and higher COX2 gene expression in the advanced stages of the disease. The results also indicated that COX2 expression level could affect carcinogenicity by modulating local inflammation (43). In addition, a case–control study on Iraqi patients reported that the expression level of COX2 was upregulated at higher tumor grades (44). This result suggests that considering COX2 as an early marker of progression or initiation of colorectal carcinoma should be investigated by further studies. Moreover, Labda et al. found that COX2 expression was associated with tumor size and degree of differentiation in an observational study including 58 Indonesian CRC patients. However, there was no statistical correlation between COX2 expression and tumor location (45). Jin et al. conducted a case-control study involving 213 Chinese patients with colorectal cancer and 200 controls and reported that the expression level of IGF-1R and COX2 was directly related
to the degree of progression and lymphatic metastasis and inversely related to the mean survival rate in CRC patients (46). The results of a Chinese study also indicated that $PGE_2$ and COX2 expression were significantly associated with tumor invasion, tumor differentiation, lymph node metastasis, and TNM stage and were inversely related to patient survival (47).

Polymorphisms of the COX gene can affect the risk of CRC. In this regard, Lin et al. found that the COX2 rs5273 polymorphism, in about 5% of African Americans, was associated with a lowered risk of CRC (OR = 0.78, 95% CI: 0.49–1.23) (26). The COX2 rs4648298 and rs689469 polymorphisms were reported to be associated with an increased risk of CRC. Analysis of haplotypes confirmed that people with these variants were at an increased risk of colorectal cancer (OR = 2.17, 95% CI: 0.97–4.84, P = 0.06) (27). In contrast with these results, Mosallaei et al. observed a significant relationship between COX2 rs4648298 polymorphism (AA genotype) and a reduced risk of CRC in the Iranian population (OR = 0.14; 95% CI: 0.05–0.34; P < 0.001). Interestingly, they found this significant association only in non-smokers (28). This finding suggests that environmental factors may influence the association between the COX gene polymorphism and CRC. Another study showed that the GG genotype of COX2 rs20417 was associated with an increased risk of developing CRC in the Dutch population (OR, 1.45; 95% CI, 1.03–2.04) (30). Interestingly, Xing et al. observed the positive association between the GG genotype of the COX2 rs20417 polymorphism and increased CRC risk in China, especially in smokers and in people with a high Body Mass Index (BMI) (OR: 1.107, 95% CI: 1.107–3.726; P = 0.022) (31). In this line, the Minnesota-based case-control study discovered that COX2 gene expression or COX2 enzyme activity is suppressed and the risk of colorectal polyps is reduced by NSAIDs in individuals with the GG genotype of COX2 rs20417 (OR: 0.66; 95% CI: 0.48–0.92) (29). Ueda et al. investigated the association between the COX2 position 765 G>C, 8473 T>C, and 9850 A>G and CRC risk and reported that among the studied polymorphisms, COX2 8473T>C may reduce the CRC risk in people who consume NSAIDs (OR: 1.57, 95% CI: 1.04–2.38) (32). Another previous study on 104 cases of adenomatous polyps and 115 matched control samples found that COX2 rs689466 polymorphism may have a protective effect on the risk of development of CRC (33).

In contrast, Peters et al. identified that overrepresentation of COX2 was associated with a high risk for CRC development in patients with familial adenomatous polyposis (FAP) who had the rs689466 polymorphism (GG genotype) and a reduced risk of CRC in the Iranian population (OR = 0.14; 95% CI: 0.05–0.34; P < 0.001). Interestingly, Xing et al. observed the positive association between the GG genotype of COX2 rs20417 (OR: 0.66; 95% CI: 0.48–0.92) (29). Ueda et al. investigated the association between the COX2 polymorphism and CRC risk.

### Interaction Between CRC, ALOX and COX Polymorphisms, and Dietary Fatty Acids

COX enzymes (COX1, COX2) are important factors in the biosynthetic pathway of PGs from AA. ALOX enzymes (ALOX5, ALOX12, and ALOX15) convert PUFA to fatty acid hydroperoxides, which results in the production of LTs. Recent studies reported an association between the CRC risk with the amount of fatty acids intake and COX and ALOX polymorphisms (Figure 4). Habermann et al. identified an association between COX1 rs10306110 polymorphism and low intake of docosahexaenoic acid (DHA), a fatty acid with anti-inflammatory properties, with an increased risk of colon cancer (OR = 1.6, 95% CI: 1.1–2.3, adjusted $P = 0.06$) (38).
Notably, supplementation with some fatty acids such as ω-3 fatty acids plays a protective role in colon cancer by attenuating the pro-inflammatory state and decreasing the production of PGE$_2$ (48). These results conform to studies that indicated that omega-3 long-chain polyunsaturated fatty acids (n–3 LC-PUFA) may lower cancer risk by suppressing oxidative stress, tumor apoptosis, and inflammatory pathways by modulation of COX activity and inhibition of arachidonic acid-derived eicosanoids (49–51). However, a case–control study on 310 patients with colorectal cancer and 1,177 controls provided epidemiological evidence for the possible link between PGI$_2$ production from n–6 PUFAs through the enzymatic activity of COX2 and increased risk of colon cancer. They reported an association between COX2 rs20417 polymorphism and an increased risk of colon cancer in individuals with high n–6 PUFAs intake (OR = 2.38, 95% CI = 1.23–4.59, P = 0.07). However, there was no association between this polymorphism and the risk of rectal cancer regardless of the dietary n–6 PUFAs intake levels (52). These results emphasize the importance of lifestyle modification in the carriers of the high-risk allele of the COX gene. Moreover, Siezen et al. demonstrated that colorectal adenoma risk could be modified by the interaction between polymorphisms in AA pathway genes and fish consumption. They showed that the COX2 rs5277 polymorphism in people with high fish consumption played a protective role against CRC compared with people with low fish intake (53). In another work, Siezen et al. confirmed the inverse association between high fish consumption and CRC risk. However, they could not find any significant interaction between CRC and SNPs in the genes involved in the AA pathway (54). Interestingly, another study indicated that the effects of n–3 PUFAs intake and NSAIDs on CRC may differ in people with COX1 polymorphisms. Among the wild-type homozygous individuals (PP genotype) with COX1 rs3842787 polymorphism, high fish consumption and regular use of NSAIDs were associated with a decreased risk of CRC. In comparison, an inverse association was observed in individuals with at least one risk allele (PL, LL genotypes) in the COX-1 rs3842787 polymorphism (55). Furthermore, dietary supplementation with n–3 PUFAs, particularly DHA and EPA, was reported to have antineoplastic effects on CRC by modifying the epigenetic modification like DNA methylation (56). Table 3 summarizes studies regarding the association between ALOX, COX polymorphism, dietary fatty acid, and CRC risk.

Regarding the interactions between ALOX and COX gene polymorphisms, Siezen et al. reported that these SNPs are associated with colorectal adenoma risk and that these associations are modified by fish consumption. No association was found between SNP rs5277 in the COX2 gene and rs743646 in the ALOX15 gene (53).

**DISCUSSION**

The results of this study indicated that some SNPs of the ALOX and COX genes can be associated with the interaction between dietary fats and the risk of CRC. The metabolizing effects of ALOX and COX enzymes on AA were reported to be associated with the production of carcinogenic factors in the colon (57). The association between ALOX12 and colorectal neoplasia has been reported (22). However, Goodman et al. found that the ALOX5 gene haplotype, including the rs6413416 and rs4986632 polymorphisms, was associated with a reduced risk of CRC in Caucasians. They assumed that these polymorphisms could augment the binding to the regulatory region of the promoter. Thus, attenuating the enzymatic activity could lead to a lower cancer risk. While this association was not observed in the African-American population, this inconsistency can be related to the existence of effective genetic or environmental factors in the African-American population (8).

Concerning the role of the COX enzyme in CRC risk, it has been reported that COX2 is involved in the early stages of colon cancer development (42). Low COX2 expression is observed in the early stages of colon cancer and COX2 overexpression is more common in the advanced stages of the disease (43). COX2 expression was significantly associated with CRC tumor invasion, tumor location, tumor size, degree of differentiation, and metastasis (45, 58). However, there was no significant relationship between COX2 expression and the histological type of CRC (45). On the other hand, an inverse association was reported between CRC with COX2 expression as well as methylation patterns within the promoter regions of COX2 (42). Regarding the association between CRC and COX2 genotype, some studies found no association between rs20420 and rs5273 polymorphisms of the COX2 gene and CRC risk (8, 59). In contrast, Lin and Schumaf reported the protective effect of COX2 rs689466 and rs5273 polymorphisms against colorectal neoplasms (26, 33), and some other studies reported an increased risk of CRC carriers of some COX2 polymorphisms such as rs689466 and rs20417 (31, 32, 35, 43). These conflicting results of the studies can be due to differences in ethnicity, environmental factors, and tumor type.

The role of polyunsaturated fatty acids (PUFAs) in the prevention of various types of malignancy, such as CRC, has been frequently reported (56). Recent studies found that dietary fatty acids may influence the association between CRC with ALOX and COX genes. For example, Habermann et al. indicated the effects of different fatty acid intake patterns on the association between colon cancer risk and COX1 rs10306110 and ALOX15 rs11568131 polymorphisms and also on the association between rectal cancer risk and COX1 rs10306122 and ALOX12 rs11571339 polymorphisms. They reported a possible increase in CRC risk among those with low intake of the marine sources of n–3 PUFAs such as EPA and DHA in people with a risk allele of COX1 rs10306110 polymorphism (38). The evidence indicates that n–3 LC-PUFA may decrease cancer risk by suppressing oxidative stress, tumor apoptosis, and inflammatory pathways. They can decrease inflammation via the modulation of COX activity and inhibition of arachidonic acid-derived eicosanoids (49–51). It has also been reported that consuming higher n–3 fatty acids may reduce the production of pro-inflammatory eicosanoids, which may be involved in colon cancer (17). In this regard, Wilson et al. reported that ω-3 fatty acid...
supplementation upregulated COX1 expression and reduced the pro-inflammatory state. Individuals with higher mRNA expression of COX2 after ω-3 fatty acid supplementation had reduced colonic PGE2 (48). The ALOX and COX gene expression level in CRC patients is supposed to be dependent on dietary fats. Koh et al. provided epidemiological evidence for a possible association between the production of prostaglandin n–6 PUFAs through COX2 enzymatic activity and an increased risk of colon cancer. They also showed a significant association between the COX2 rs20417 and colorectal cancer risk among people with a higher intake of n–6 PUFAs (52). The ratio of omega-6 fatty acids (as precursors of inflammatory eicosanoids) to omega-3 fatty acids (as precursors of anti-inflammatory eicosanoids) may affect the extent to which the ALOX and COX genes affect colorectal cancer risk. These results highlight the importance of the intake of different types of dietary fats in carriers of the risk alleles of the ALOX and COX genes. However, few studies directly assess this interaction. Also, different factors, such as ethnic and racial differences, may influence the obtained results on the interactions of CRC risk with dietary fats and ALOX and COX genes. Further studies are needed to understand the interaction between dietary fat, genetics, and colorectal cancer. Moreover, other genes involved in enzymatic pathways for synthesizing eicosanoids from dietary fats and possible mechanisms for their relationship with CRC risk should be investigated. If the findings of this review study are confirmed in future longitudinal studies, it could be an important step in providing a specific diet to prevent colorectal cancer, especially in COX and ALOX risk allele carriers.

### CONCLUSION

In conclusion, COX and ALOX genes may play a significant role in CRC risk. Additionally, dietary fats may play an essential role in the effects of the ALOX and COX genes on the risk of CRC. Generally, enhancing the knowledge of nutritional genomics can lead to finding new methods to prevent, treat, and manage CRC. The results of this review article emphasize that environmental factors, such as dietary fat intake, may influence the association between colorectal cancer and the genotype of an individual. If the results are confirmed in future longitudinal studies, the importance of personalized medicine and the recommendation

| Study | Ethnicity | Study design | Case/Control | Polymorphisms | Main finding |
|-------|-----------|--------------|--------------|---------------|-------------|
| Habermann et al. (38) | American | Case–control study | 1,574 colon cancer and 791 rectal cancer and 2969 control | COX1 (rs10306110 and rs10306122), COX2 (rs4648276), ALOX15 (rs11568131) | There was a positive association between low intake of DHA and increased risk of colon cancer with COX1 rs10306110. There was a positive association between higher inflammatory score and increased risk of colon cancer with wild type ALOX15 rs11568131. There was an inverse association between low total fat intake and rectal cancer risk with COX1 rs10306122. There was an inverse association between low inflammatory score and rectal cancer risk with COX2 rs4648276. |
| Wilson et al. (48) | American | Cross-sectional study | 90 participant | PTGS | Supplementation of some kind of fatty acids like ω-3 fatty acids can have a protective role in colon cancer by decreasing the production of PGE2. |
| Koh et al. (52) | Asian | Nested Case–control study | 310 colorectal cancer cases and 1177 controls | COX2 rs20417 | It was a statistically significant association between COX2 rs20417 polymorphism and CRC risk among high consumers of dietary n–6 PUFAs. |
| Siezen et al. (53) | Netherlands | Case–control study | 384 cases and 403 poly-p-free controls | COX2 rs5277 | COX2 rs5277 polymorphism in people with high consumption of fish had a protective role against CRC compared with people with low fish intake. |
| Siezen et al. (54) | Netherlands | Case–control study | 508 cases and 772 controls | PTGS1 and PTGS2 | Although there was a significant reduction in cancer risk for individuals with COX2 rs5277 in combination with high fish intake, no significant interaction was observed between the SNPs in genes involved in AA metabolism and fish intake. The results suggested that among individuals with the wild-type homozygous (PP) in COX1 rs3842787, increased fish consumption was associated with a slight reduction in the risk of adenoma, Whereas among people who had at least one different allele (LL, PL) in COX1 rs3842787, an inverse association was observed. |
| Poole et al. (55) | Minneapolis | Case–control study | 522 adenomas, 194 hyperplastic polyps and 626 poly-p-free controls | COX -1 rs3842787 | COX -1 rs3842787, increased fish consumption was associated with a slight reduction in the risk of adenoma, Whereas among people who had at least one different allele (LL, PL) in COX1 rs3842787, an inverse association was observed. |
| Sarabi et al. (56) | Shiraz, Iran | Cell culture | 5 human CRC cell lines | Polyunsaturated fatty acids DNA methylation (DNMT) | PUFAs significantly suppressed DNMT3a and DNMT3b expression in SW742 cells (p < 0.05) and PUFAs treatment tends to coordinately suppress the expression of DNMTs in four CRC cell lines. |

COX, Cyclooxygenase; ALOX, Arachidonic Acid Lipoxygenase; DHA, Docosahexaenoic acid; PTGS, Prostaglandin-Endoperoxide Synthase; CRC, Colorectal cancer; PUFAs, Polyunsaturated fatty acids; DNMT, DNA methyltransferases.
of personalized diets according to the genotype of individuals to prevent colorectal cancer will be further highlighted. Further longitudinal studies in this field of nutritional genomics can lead to the discovery of personalized dietary recommendations for CRC prevention.

AUTHOR CONTRIBUTIONS
MG, SMD, and AH designed the study, and were involved in the data collection, analysis, and drafting of the manuscript. NM, SA, SA, SP, MNJ, SD, HS, MH, MA, and AA were involved in the design of the study, analysis of the data, and critically reviewed the manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

REFERENCES
1. Becker N. Epidemiology of Colorectal Cancer. *Der Radiologe* (2003) 43(2):98–104. doi: 10.1007/s00117-003-0868-9
2. Xi Y, Xu P. Global Colorectal Cancer Burden in 2020 and Projections to 2040. *Trans Oncol* (2021) 14(10):101174. doi: 10.1016/j.tranon.2021.101174
3. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wall A. Dietary Long-Chain N–3 Fatty Acids for the Prevention of Cancer: A Review of Potential Mechanisms. *Am J Clin Nutr* (2004) 79(6):935–45. doi: 10.1093/ajcn/79.6.935
4. Marley AR, Nan H. Epidemiology of Colorectal Cancer. *Int J Mol Epidemiol Genet* (2016) 7(3):105.
5. Vinikoor LC, Milkman RC, Satia JA, Schroeder JC, Martin CF, Ibrahim JG, et al. Trans-Fatty Acid Consumption and Its Association With Distal Colorectal Cancer in the North Carolina Colon Cancer Study II. *Cancer Causes Control* (2010) 21(1):171–80. doi: 10.1007/s10552-009-9447-3
6. Whelan J, McEntee MF. Dietary (N-6) PUFA and Intestinal Tumorigenesis. *J Nutr* (2004) 134(12):3421S–6S. doi: 10.1093/jn/134.12.3421S
7. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, et al. Dietary-Fat-Induced Taurocholic AcidPromotes Pathobiont Expansion and Colitis in Il10–/– Mice. *Nature* (2012) 487(7405):234–41. doi: 10.1038/ nature11225
8. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC. Arachidonic Lipoxygenase (ALOX) and Cyclooxygenase (COX) Polymorphisms and Colon Cancer Risk. *Carcinogenesis* (2004) 25(12):2467–72. doi: 10.1093/carcin/bgh260
9. Calder PC. Eicosanoids. *Essays Biochem* (2020) 64(3):423–41. doi: 10.1042/ EBC20190083
10. Dosei S, Kalantari N, Izadi P, Salonurmi T, Mosavi Jarrahi A, Ra...
29. Ulrich CM, Whitton J, Yu J-H, Sibert J, Sparks R, Potter JD, et al. PTGS2 (COX-2) – 765G>C Promoter Variant Reduces Risk of Colorectal Adenoma Among Non-users of Non-steroidal Anti-inflammatory Drugs. Cancer Epidemiol Prev Biomarkers (2005) 14(3):616-9. doi: 10.1158/1055-9966.EPI-04-0310

30. Hoff JH, Te Morsche RH, Roelofs HM, van der Logt EM, Nagengast FM, Peters WH. COX-2 Polymorphisms – 765G>C and -1195A>G and Colorectal Cancer Risk. *World J Gastroenterol* (2009) 15(36):4561. doi: 10.3748/wjg.15.4561

31. Xing L-L, Wang Z-N, Jiang L, Zhang Y, Xu Y-Y, Li J, et al. Cyclooxygenase 2 Genetic Polymorphisms and the Risk of Sporadic Colorectal Cancer and Polyps Among Jordanian Population. *Turk J Gastroenterol* (2015) 26(2):154–8. doi: 10.5135/tjg.2015.6174

32. Peters WH, te Morsche RH, Roelofs HM, Mathus-Vliegen EM, Berkhou M, Nagengast FM. COX-2 Polymorphisms in Patients With Familial Adenomatous Polyposis. *Oncol Res* (2009) 17(6):347–51. doi: 10.3727/096060109X465131

33. Pereira C, Queiroz S, Galagarah A, Sousa H, Pimentel-Nunes P, Brandoa C, et al. Genetic Variability in Key Genes in Prostaglandin E2 Pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and Their Involvement in Colorectal Cancer Development. *PloS One* (2014) 9(4):e92000. doi: 10.1371/journal.pone.0092000

34. Chakrabarti SK, Cole BK, Wen Y, Keller SR, Nadler JL. Genetic Variability of Cyclooxygenase-2 (COX2) Gene Polymorphisms and the Risk of Sporadic Colorectal Cancer and Polyps Among Jordanian Population. *Turk J Gastroenterol* (2015) 26(2):154–8. doi: 10.5135/tjg.2015.6174

35. Silverman ES, Drazen JM. Genetic Variations in the 5-Lipoxygenase Core Promoter: Description and Functional Implications. *Am J Respir Cell Mol Med* (2000) 161(supplement_1):S77–80. doi: 10.1165/ajrccm.161.supplement_1.s1a-16

36. Habermann N, Ulrich CM, Lundgreen A, Makar KW, Poole EM, Caan B, et al. PTGS1, PTGS2, ALOX5, ALOX12, ALOX15, and FLAP SNPs: Interaction With Fatty Acids in Colon and Rectal Cancer. *Genes Nutr* (2013) 8(1):115–26. doi: 10.1007/s12623-012-0302-x

37. Brenna JT, Salem N, Sinclair AJ, Cunnane SC. α-Linolenic Acid Supplementation and Conversion to N-3 Long-Chain Polyunsaturated Fatty Acids in Humans. *Prostaglandins Leukotrienes Essential Fatty Acids* (2009) 80(2–3):85–91. doi: 10.1016/j.prostaglandins.2009.01.004

38. Salem AM, Efeky MA, Nawar N, Alattar AZ, Elebki OA, Elaidy MM. Prognostic Value of Combined: COX-2, Cyclin D1 and F21 Expression in Colorectal Cancer (CRC) Patients: An Immunohistochemical Study. *Open J Pathol* (2018) 8(3):106–21. doi: 10.4236/ijpathology.2018.83013

39. Wasti H, Sharwana S. Comparison Of BRAF V600E, COX-2 and P53 As Biomarkers For The Early Detection Of Colorectal Cancer. *Bahrain Univ Med Dent Coll* (2019) 9(2):147–50. doi: 10.51985/BUMDC2019017

40. Ayiomamitis GD, Notas G, Vasilakaki T, Tsavari A, Vederaki S, Joanna B, Jolanta B, Agnieszka G, Diana H-Z, Krystyna S, et al. Linoleic Acid, Adipocytes. *Prostaglandins Leukotrienes Essential Fatty Acids* (2014) 86(1):1760–4. doi: 10.1136/ijgutjnl-2013-306445

41. ZS Madhloom, AK Melconian and AS Mahmood. The Impact of Polyunsaturated Fatty Acids on DNA Methylation and Expression of DNMTs in Human Colorectal Cancer Cells. *Biomed Pharmacother* (2018) 101:94–9. doi: 10.1016/j.biopha.2018.02.077

42. Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, Doeselar M, van Kranen HJ, Kampman E. Colorectal Adenoma Risk Is Modified by the Interplay Between Polyunsaturated Fatty Acids in Arachidonic Acid Pathway Genes and Fish Consumption. *Carcinogenesis* (2005) 26(2):449–57. doi: 10.1093/carcin/bgh336

43. Austin Pickens C, Yin Z, Sordillo LM, Fenton JL. Arachidonic Acid-Derived Hydroxyicosatetraenoic Acids Are Positively Associated With Colon Polyps in Adult Males: A Cross-Sectional Study. *Sci Rep* (2019) 9(1):1–10. doi: 10.1038/s41598-019-48384-0

44. MA J, Zhao X-QI, Guo Q, Gong Z, DU J, et al. Expression of PGE2 and COX-2 in Colorectal Cancer and the Clinical Significance. *Chin J Gen Surg* (2018) 322–5.

45. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA. Functional Characterization of Cyclooxygenase-2 Polymorphisms. *J Pharmacol Exp Ther* (2001) 299(2):468–76.

46. Jiachi M, Zhao X, Jianbo Q, Guo Q, Gong Z, Jianbo D, et al. Expression of PGE2 and COX-2 in Colorectal Cancer and the Clinical Significance. *Chin J Med Surgery* (2018) 33(4):325–6.

47. Wilson MJ, Sen A, Bridges D, Turgeon DK, Brenner DE, Smith WL, et al. Higher Baseline Expression of the PTGS2 Gene and Greater Decreases in Total Colonic Fatty Acid Content Predict Greater Decreases in Colonic Prostaglandin-E2 Concentrations After Dietary Supplementation With ω-3 Fatty Acids. *Prostaglandins Leukotrienes Essential Fatty Acids* (2018) 139:14–9. doi: 10.1016/j.prolefa.2018.11.001

48. Yurko-Mauro K, Van Elswyk M, Teo L. A Scoping Review of Interactions Between Omega-3 Long-Chain Polyunsaturated Fatty Acids and Genetic Variation in Relation to Cancer Risk. *Nutrients* (2020) 12(6):1647. doi: 10.3390/nu12061647

49. Cockbain AJ, Volpato M, Race AD, Munarini A, Fazio C, Belluzi A, et al. Anticancer Cancer Activity of the Omega-3 Polyunsaturated Fatty Acid Eicosapentaenoic Acid. *Gut* (2013) 62(11):1760–4. doi: 10.1136/gutjnl-2013-306445

50. Mauermann J, Poulloft F, Fradet V. Dietary Omega-3 Fatty Acids, Genetic Variation and Risk of Breast and Prostate Cancers. *Healthy Agriculture Healthy Nutrition Healthy People* (2011) 102:156–71. doi: 10.1158/1055-9965.EPI-04-0510

51. Koh W, Yuan J, Van Den Berg D, Lee H, Yu M. Interaction Between Cyclooxygenase-2 Gene Polymorphism and Dietary N-6 Polyunsaturated Fatty Acids on Colon Cancer Risk: The Singapore Chinese Health Study. *Br J Cancer* (2004) 90(9):1760–4. doi: 10.1038/sj.bjc.6601779

52. Labeda I, Uwurutu JA, Nwafor F, van der Meulen HJ, van der Hoeven DJ, Houshiar-Rad. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.